New hope for stomach cancer patients who have run out of options?
NCT ID NCT07364422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called JPI-547 combined with irinotecan for people with advanced stomach cancer that has come back or spread after at least two prior treatments. The goal is to see if the combination is safe and can shrink tumors. About 49 adults with good performance status will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Can an immune booster shrink Hard-to-Treat stomach tumors?
- Electric acupoint therapy may speed digestion and ease pain after stomach cancer surgery
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- New PET tracer aims to spot hidden cancer spread in the abdomen